New eye drops for nearsightedness pass early safety check
NCT ID NCT05470881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested the safety of PRO-201 eye drops (a low-dose atropine solution) in 29 healthy adults aged 18 to 35. The main goal was to see if the drops cause unexpected side effects or light sensitivity. Researchers also checked vision, eye pressure, and comfort. The study is complete, but results are not yet available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOPIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IIMET Investigación e Innovación en Medicina Traslacional
Guadalajara, Jalisco, 44610, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart glasses aim to stop nearsightedness before it starts
- Can a pair of glasses slash motorcycle crashes?
- Virtual streets could shape Kids' vision and feelings
- Can a new lens design improve overnight vision correction?
- Ear seeds and smart glasses: a new hope to halt childhood myopia?
- Red light therapy for nearsighted kids: what happens when it stops?